Mostra i principali dati dell'item
Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice
dc.creator | Mitsikostas D., Bakirtzis C., Nikolaidis I., Tsimourtou V., Kountra P., Matsi S., Papadimitriou A. | en |
dc.date.accessioned | 2023-01-31T09:00:39Z | |
dc.date.available | 2023-01-31T09:00:39Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.2217/nmt-2022-0004 | |
dc.identifier.issn | 17582024 | |
dc.identifier.uri | http://hdl.handle.net/11615/76685 | |
dc.description.abstract | Aim: To evaluate glatiramer acetate (GA) or IFN-β effects on quality of life (QoL) in people with relapsing/remitting multiple sclerosis (PwRRMS) in Greece. Methods: A prospective, practice-based study. QoL/function/symptoms were assessed by seven questionnaires/scales. Results: Significant increases in Short Form-36 (SF-36) health survey scores occurred with GA in four of the eight domains and three of the eight domains at 6 and 12 months, respectively, versus baseline. Similar and significant SF-36 score improvements occurred with GA in treatment-naive PwRRMS. SF-36 scores were unaffected in GA-treated, IFN-β treatment-experienced PwRRMS, or with IFN-β versus baseline. Slight improvements in fatigue and sexual satisfaction were evident (6 months). No deteriorations were seen in the other four instruments. Conclusion: The findings show that 12-month treatment with GA, but not IFN-β, improved certain QoL parameters in treatment-naive PwRRMS. Plain language summary People with relapsing/remitting multiple sclerosis (PwRRMS) are treated with drugs, for example, glatiramer acetate (GA) or IFN-β. We checked if these drugs improved quality of life (QoL) in PwRRMS in Greece. QoL was measured by seven questionnaires, asking many questions on aspects of life. One survey showed significant improvements with GA treatment in almost half of the question groups. Similar improvements in this survey were seen with GA in patients who had no other previous treatments. No changes were seen in GA-treated PwRRMS who previously received IFN-β, or treated with IFN-β alone. Slight improvements in fatigue and sexual satisfaction were seen. No QoL deteriorations were seen in the other four questionnaires. Twelve months of GA treatment, but not IFN-β, improved certain QoL parameters in treatment-naive PwRRMS. © 2022 Future Medicine Ltd. | en |
dc.language.iso | en | en |
dc.source | Neurodegenerative Disease Management | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85142422991&doi=10.2217%2fnmt-2022-0004&partnerID=40&md5=acf7341c2784767125872a8c8eb6c6c8 | |
dc.subject | beta interferon | en |
dc.subject | gamma glutamyltransferase | en |
dc.subject | glatiramer | en |
dc.subject | adolescent | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | breast cancer | en |
dc.subject | child | en |
dc.subject | clinical outcome | en |
dc.subject | clinical practice | en |
dc.subject | cohort analysis | en |
dc.subject | controlled study | en |
dc.subject | depression | en |
dc.subject | drug withdrawal | en |
dc.subject | dysesthesia | en |
dc.subject | Expanded Disability Status Scale | en |
dc.subject | fatigue | en |
dc.subject | female | en |
dc.subject | fever | en |
dc.subject | flu like syndrome | en |
dc.subject | follow up | en |
dc.subject | Greece | en |
dc.subject | health survey | en |
dc.subject | human | en |
dc.subject | injection site reaction | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | multicenter study | en |
dc.subject | multiple sclerosis | en |
dc.subject | nausea | en |
dc.subject | observational study | en |
dc.subject | paresthesia | en |
dc.subject | propensity score | en |
dc.subject | prospective study | en |
dc.subject | quality of life | en |
dc.subject | questionnaire | en |
dc.subject | sexual satisfaction | en |
dc.subject | shivering | en |
dc.subject | Short Form 36 | en |
dc.subject | side effect | en |
dc.subject | weakness | en |
dc.subject | Newlands Press Ltd | en |
dc.title | Quality of life in people with multiple sclerosis receiving glatiramer acetate or interferon in Greek clinical practice | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |